Business Update21 Jul 2025, 08:27 am
Sun Pharma's Phase 3 Clinical Studies for Tildrakizumab 100 mg in Active Psoriatic Arthritis Successful
AI Summary
Sun Pharmaceutical Industries Limited announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) administered over 24 weeks for treatment of active psoriatic arthritis. The INSPIRE-1 and INSPIRE-2 studies met their primary endpoint, with a higher proportion of patients achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05). The safety data was consistent with the well-documented safety profile of ILUMYA. No new safety signals were identified in the INSPIRE-1 and INSPIRE-2 studies.
Key Highlights
- Sun Pharma's Phase 3 clinical studies for Tildrakizumab 100 mg in active psoriatic arthritis met their primary endpoints.
- The INSPIRE-1 and INSPIRE-2 studies achieved higher ACR20 responses at week 24 with tildrakizumab 100 mg compared to placebo.
- The safety data was consistent with the well-documented safety profile of ILUMYA.
- No new safety signals were identified in the INSPIRE-1 and INSPIRE-2 studies.
- The findings from the INSPIRE studies will be presented at upcoming medical conferences and published in a peer-reviewed medical journal.